bioAffinity Technologies Inc. (NASDAQ: BIAF) stock jumped 75.47% on Tuesday to $2.79 against a previous-day closing price of $1.59. With 68.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 63600.0 shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $3.9900 whereas the lowest price it dropped to was $1.7000. The 52-week range on BIAF shows that it touched its highest point at $15.55 and its lowest point at $1.31 during that stretch.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIAF was up-trending over the past week, with a rise of 73.29%, but this was up by 65.09% over a month.
Float and Shares Shorts:
At present, 8.37 million BIAF shares are outstanding with a float of 6.22 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.11 million, which was 3.86% higher than short shares on Sep 14, 2022. In addition to Ms. Maria Zannes J.D. as the firm’s Founder, Pres, CEO & Director, Dr. Vivienne I. Rebel M.D., Ph.D. serves as its Exec. VP and Chief Medical & Science Officer.
Through their ownership of 0.00% of BIAF’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 25.03% of BIAF, in contrast to — held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in BIAF with 0.35% of the stake, Creative Planning LLC holds 29,545 shares worth 29,545. A second-largest stockholder of BIAF, Citadel Securities LLC, holds 20,583 shares, controlling over 0.25% of the firm’s shares. Jane Street Capital LLC is the third largest shareholder in BIAF, holding 11,004 shares or 0.13% stake.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIAF since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.. Analysts have provided yearly estimates in a range of -$1.94 being high and -$1.94 being low. For BIAF, this leads to a yearly average estimate of -$1.94. Based on analyst estimates, the high estimate for the next quarter is -$0.19 and the low estimate is -$0.19. The average estimate for the next quarter is thus -$0.19.
Summary of Insider Activity:
Insiders traded BIAF stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 32,576 shares were bought while 0 shares were sold. The number of buy transactions has increased to 35 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 1,498,370 while 0 shares were sold.